Paul L. Berns, President and CEO at Anacor Pharmaceuticals, Inc. (ANAC), sold 55,000 shares at $66.31 ($3.2M) on 2015-04-24, disclosed to the SEC on 2015-04-28.
Scheduled sale ($3.2M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 5,000 | $0 | 0.0% |
| 2 | $64.69 | 7,833 | $507K | 15.9% |
| 3 | $65.51 | 16,267 | $1.1M | 33.5% |
| 4 | $66.31 | 900 | $60K | 1.9% |
| 5 | $59.79 | 7,624 | $456K | 14.3% |
| 6 | $60.46 | 2,078 |
| $126K |
| 3.9% |
| 7 | $61.74 | 2,100 | $130K | 4.1% |
| 8 | $62.68 | 3,448 | $216K | 6.8% |
| 9 | $63.85 | 9,750 | $623K | 19.6% |
| Total | $57.85 avg | 55,000 | $3.2M | 100% |
| Filing → |
| NMRA | SELL | 2026-02-19 | $34K | — | Filing → |
| NMRA | SELL | 2025-02-20 | $23K | — | Filing → |
| MTSR | BUY | 2025-02-03 | $14.2M | — | Filing → |